Evidence mapPaperPMID 40576003Full record

Observational studyLiver international : official journal of the International Association for the Study of the Liver2025

Impact of Socio-Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B.

Clémence Ramier, Anders Boyd, Colette Smit, Rosan van Zoest, Mark A A Claassen, Katalin Pogány, Dirk Posthouwer, Theodora E M S de Vries-Sluijs, Patrizia Carrieri, Marc Van der Valk

Abstract readObservational Study
In one paragraph

Observational study in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Impact of Socio-Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clémence RamierAix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de L'information Médicale, ISSPAM, Marseille, France.ORCID 0000-0002-1928-0263
Anders BoydDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0001-9512-8928
Colette SmitAmsterdam UMC, Location University of Amsterdam, Amsterdam Institute for Immunology & Infectious Diseases, Infectious Diseases Program, Amsterdam, the Netherlands.
Rosan van ZoestAmsterdam Health and Technology Institute, Amsterdam, the Netherlands.
Mark A A ClaassenRijnstate Hospital, Department of Internal Medicine, Infectious Diseases Unit, Arnhem, the Netherlands.ORCID 0000-0002-8824-3722
Katalin PogányDepartment of Internal Medicine, Infectious Diseases Unit, Maasstad Hospital, Rotterdam, the Netherlands.
Dirk PosthouwerDepartment of Internal Medicine and Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht UMC +, the Netherlands.
Theodora E M S de Vries-SluijsDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
Patrizia CarrieriAix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de L'information Médicale, ISSPAM, Marseille, France.
Marc Van der ValkDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsLittle is known about the contribution of sociodemographic and behavioural factors to developing liver disease in individuals with an HIV and chronic hepatitis B virus (HBV) co-infection. We aimed to quantify the impact of these factors on incident liver disease in individuals with HIV/HBV receiving care in the Netherlands.

methodsWe used data from the Dutch observational ATHENA cohort combined with Statistics Netherlands. We included all hepatitis B surface antigen-positive individuals with HIV in care from 2008-2022. Severe liver disease (i.e., significant fibrosis (≥F2), cirrhosis, hepatocellular carcinoma, liver transplantation) was defined by physician diagnosis or a transient elastography result > 7 kPa. Determinants of incident liver disease were assessed using Cox proportional hazard models.

resultsIn the 1319 individuals included (12,277 person-years (PY); 93.3% HIV-RNA < 200 copies/ml), the incidence rate of severe liver disease was 0.59 per 100 PY [95% confidence interval (CI) = 0.47-0.75]. After adjustment for age and time since HBV diagnosis, tobacco smoking, HCV coinfection and body mass index > 25 kg/m

conclusionsLiver disease progression in people living with HIV/HBV appears to be linked to psychosocial/behavioural factors. More effective screening/management of coinfection and metabolic syndrome, as well as strategies for smoking cessation, should be included in clinical follow-up.

Indexed as

CoinfectionHepatitis B, ChronicHIV InfectionsLiver CirrhosisAdultCarcinoma, HepatocellularDisease ProgressionFemaleHumansIncidenceLiver NeoplasmsMaleMiddle AgedNetherlandsProportional Hazards ModelsRisk FactorsbehaviourhepatitisHIVliver diseasesocioeconomyurbanisation

Identifiers

PMID40576003
PMCPMC12203455

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.